Demographics and general characteristics of the patients
| Variable . | Results . |
|---|---|
| Pretransplantation variables (n = 64 patients) | |
| Median age at diagnosis, y (range) | 43 (16-67) |
| Median age at T315I detection, y (range) | 44 (22-66) |
| Median age at transplantation, y (range) | 46 (22-68) |
| Male/female, n (%) | 47 (73.5)/17 (26.5) |
| Disease status, n (%) | |
| CP of CML | |
| At diagnosis | 42 (65.5) |
| At imatinib initiation | 36 (56) |
| At T3151 detection | 18 (28) |
| At transplantation | 33 (51.5) |
| AP of CML | |
| At diagnosis | 1 (1.5) |
| At imatinib initiation | 4 (6) |
| At T3151 detection | 10 (16) |
| At transplantation | 9 (14) |
| Blast crisis (lymphoid+myeloid) CML | |
| At diagnosis | 4 (6) |
| At imatinib initiation | 4 (6) |
| At T3151 detection | 15 (23) |
| At transplantation | 17 (26.5) |
| De novo Ph+ ALL | |
| At diagnosis | 5 (8) |
| At imatinib initiation | 5 (8) |
| At T3151 detection | 3 (5) |
| At transplantation | 4 (6) |
| Unknown | |
| At diagnosis | 12 (19) |
| At imatinib initiation | 15 (24) |
| At T3151 detection | 18 (28) |
| At transplantation | 4 (6) |
| Median interval from disease diagnosis to imatinib initiation, mo (range) | 4 (0-823) |
| Median interval from disease diagnosis to T315I detection, mo (range) | 51.6 (0-396) |
| Median interval from imatinib initiation to T315I detection, mo (range) | 37.8 (5.3-183) |
| Median interval from T315I detection to transplantation, mo (range) | 16.3 (−28 to 204)* |
| Posttransplantation variables (n = 67 transplants) | |
| Median interval from disease diagnosis to transplantation, mo (range) | 76 (12-408) |
| Donor matching, n (%) | |
| Matched related/unrelated | 6 (9)/41 (61) |
| Mismatched related/unrelated | 5 (7)/13 (20) |
| Unknown | 2 (3) |
| Transplant type, n (%) | |
| BM | 23 (34) |
| PBSC | 34 (51) |
| Cord blood | 8 (12) |
| Unknown | 2 (3) |
| Conditioning regimen, n (%) | |
| Conventional | 40 (60) |
| RIC | 22 (33) |
| Unknown | 5 (7) |
| Transplant-related mortality according to phase | |
| 3 mo after transplantation, % (95% CI) | |
| CP | 9.1 (4-14.2) |
| AP | 0 (0-0) |
| BC | 5.9 (0-10.8) |
| Ph+ ALL | 25 (0-50) |
| 12 mo after transplantation, % (95% CI) | |
| CP | 18.2 (11.4-25.1) |
| AP | 11.1 (0-22.4) |
| BC | 35.3 (23.-47.5) |
| Ph+ ALL | 25 (0-50) |
| Variable . | Results . |
|---|---|
| Pretransplantation variables (n = 64 patients) | |
| Median age at diagnosis, y (range) | 43 (16-67) |
| Median age at T315I detection, y (range) | 44 (22-66) |
| Median age at transplantation, y (range) | 46 (22-68) |
| Male/female, n (%) | 47 (73.5)/17 (26.5) |
| Disease status, n (%) | |
| CP of CML | |
| At diagnosis | 42 (65.5) |
| At imatinib initiation | 36 (56) |
| At T3151 detection | 18 (28) |
| At transplantation | 33 (51.5) |
| AP of CML | |
| At diagnosis | 1 (1.5) |
| At imatinib initiation | 4 (6) |
| At T3151 detection | 10 (16) |
| At transplantation | 9 (14) |
| Blast crisis (lymphoid+myeloid) CML | |
| At diagnosis | 4 (6) |
| At imatinib initiation | 4 (6) |
| At T3151 detection | 15 (23) |
| At transplantation | 17 (26.5) |
| De novo Ph+ ALL | |
| At diagnosis | 5 (8) |
| At imatinib initiation | 5 (8) |
| At T3151 detection | 3 (5) |
| At transplantation | 4 (6) |
| Unknown | |
| At diagnosis | 12 (19) |
| At imatinib initiation | 15 (24) |
| At T3151 detection | 18 (28) |
| At transplantation | 4 (6) |
| Median interval from disease diagnosis to imatinib initiation, mo (range) | 4 (0-823) |
| Median interval from disease diagnosis to T315I detection, mo (range) | 51.6 (0-396) |
| Median interval from imatinib initiation to T315I detection, mo (range) | 37.8 (5.3-183) |
| Median interval from T315I detection to transplantation, mo (range) | 16.3 (−28 to 204)* |
| Posttransplantation variables (n = 67 transplants) | |
| Median interval from disease diagnosis to transplantation, mo (range) | 76 (12-408) |
| Donor matching, n (%) | |
| Matched related/unrelated | 6 (9)/41 (61) |
| Mismatched related/unrelated | 5 (7)/13 (20) |
| Unknown | 2 (3) |
| Transplant type, n (%) | |
| BM | 23 (34) |
| PBSC | 34 (51) |
| Cord blood | 8 (12) |
| Unknown | 2 (3) |
| Conditioning regimen, n (%) | |
| Conventional | 40 (60) |
| RIC | 22 (33) |
| Unknown | 5 (7) |
| Transplant-related mortality according to phase | |
| 3 mo after transplantation, % (95% CI) | |
| CP | 9.1 (4-14.2) |
| AP | 0 (0-0) |
| BC | 5.9 (0-10.8) |
| Ph+ ALL | 25 (0-50) |
| 12 mo after transplantation, % (95% CI) | |
| CP | 18.2 (11.4-25.1) |
| AP | 11.1 (0-22.4) |
| BC | 35.3 (23.-47.5) |
| Ph+ ALL | 25 (0-50) |
PBSC indicates peripheral blood stem cells; and RIC, reduced-intensity conditioning.
There were 67 transplants among 64 patients.
One patient had T315I detected after a first allogeneic SCT.